Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITESPARK-034: belzutifan + zanzalintinib versus belzutifan + placebo in previously treated advanced clear cell renal cell carcinoma
MOH_2026-02-25_015690Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing WELIREG + zanzalintinib with WELIREG + placebo (2 arms). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
belzutifanzanzalintinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2026-02-25_015690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-02-25_015690.